Lambda bacteriophage nanoparticles displaying GP2, a HER2/neu derived peptide, induce prophylactic and therapeutic activities against TUBO tumor model in mice

Razazan, Atefeh; Nicastro, Jessica; Slavcev, Roderick A.; Barati, Nastaran; Arab, Atefeh; Mosaffa, Fatemeh; Jaafari, Mahmoud Reza; Behravan, Javad

doi:10.1038/s41598-018-38371-z

Cited by 24 publications

(23 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Researchers at the University of Waterloo (Waterloo, ON, Canada) are developing a DNA-based vaccine that is administered using a nasal spray. They will use a lambda bacteriophage system for delivering DNA into target cells ( 164 , 165 ), which them produce SARS-CoV-2 VLPs that stimulate an immune response.…”

Section: Vaccine Platform Technologiesmentioning

confidence: 99%

The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies

et al. 2020

View full text Add to dashboard Cite

There is an urgent need for effective countermeasures against the current emergence and accelerating expansion of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Induction of herd immunity by mass vaccination has been a very successful strategy for preventing the spread of many infectious diseases, hence protecting the most vulnerable population groups unable to develop immunity, for example individuals with immunodeficiencies or a weakened immune system due to underlying medical or debilitating conditions. Therefore, vaccination represents one of the most promising counter-pandemic measures to COVID-19. However, to date, no licensed vaccine exists, neither for SARS-CoV-2 nor for the closely related SARS-CoV or Middle East respiratory syndrome-CoV. In addition, a few vaccine candidates have only recently entered human clinical trials, which hampers the progress in tackling COVID-19 infection. Here, we discuss potential prophylactic interventions for SARS-CoV-2 with a focus on the challenges existing for vaccine development, and we review pre-clinical progress and ongoing human clinical trials of COVID-19 vaccine candidates. Although COVID-19 vaccine development is currently accelerated via so-called fast-track programs, vaccines may not be timely available to have an impact on the first wave of the ongoing COVID-19 pandemic. Nevertheless, COVID-19 vaccines will be essential in the future for reducing morbidity and mortality and inducing herd immunity, if SARS-CoV-2 becomes established in the population like for example influenza virus.

show abstract

Section: Vaccine Platform Technologiesmentioning

confidence: 99%

The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In a second example, gpD (λ) fused to a prion protein from deer-stimulated production of IgA antibodies in a mouse model without the use of adjuvant [ 137 ]. VNPs displaying gpD (λ) fused to GP2, a peptide derivative from the overexpressed tumor protein HER2/nue, generated a strong cytotoxic T lymphocyte response that had anti-tumor activity when given prophylactically or therapeutically in a mouse model [ 138 ].…”

Section: Nanotechnology Applicationsmentioning

confidence: 99%

Keeping It Together: Structures, Functions, and Applications of Viral Decoration Proteins

Dedeo

Teschke

Alexandrescu

2020

Viruses

View full text Add to dashboard Cite

Decoration proteins are viral accessory gene products that adorn the surfaces of some phages and viral capsids, particularly tailed dsDNA phages. These proteins often play a “cementing” role, reinforcing capsids against accumulating internal pressure due to genome packaging, or environmental insults such as extremes of temperature or pH. Many decoration proteins serve alternative functions, including target cell recognition, participation in viral assembly, capsid size determination, or modulation of host gene expression. Examples that currently have structures characterized to high-resolution fall into five main folding motifs: β-tulip, β-tadpole, OB-fold, Ig-like, and a rare knotted α-helical fold. Most of these folding motifs have structure homologs in virus and target cell proteins, suggesting horizontal gene transfer was important in their evolution. Oligomerization states of decoration proteins range from monomers to trimers, with the latter most typical. Decoration proteins bind to a variety of loci on capsids that include icosahedral 2-, 3-, and 5-fold symmetry axes, as well as pseudo-symmetry sites. These binding sites often correspond to “weak points” on the capsid lattice. Because of their unique abilities to bind virus surfaces noncovalently, decoration proteins are increasingly exploited for technology, with uses including phage display, viral functionalization, vaccination, and improved nanoparticle design for imaging and drug delivery. These applications will undoubtedly benefit from further advances in our understanding of these versatile augmenters of viral functions.

show abstract

“…displaying phages (λF7 (gpD::GP2) and (λF7; gpD::AE37) induced a significant CTL response compared to λF7 and buffer groups Razazan, Nicastro, Slavcev, Barati, & Arab, 2019).…”

Section: Results Indicated That Mice Vaccinated With the Gp2 And Ae37mentioning

confidence: 98%

Single peptides and combination modalities for triple negative breast cancer

Razazan

Behravan

2019

Journal Cellular Physiology

Self Cite

View full text Add to dashboard Cite

Unlike other types of breast cancers (BCs), no specific therapeutic targets have been established for triple negative breast cancer (TNBC). Therefore, chemotherapy and radiotherapy are the only available adjuvant therapeutic choices for TNBC. New emerging reports show that TNBC is associated with higher numbers of intratumoral tumor infiltrating lymphocytes. This is indicative of host anti-TNBC immune surveillance and suggesting that immunotherapy can be considered as a therapeutic approach for TNBC management. Recent progress in molecular mechanisms of tumor-immune system interaction and cancer vaccine development studies, fast discoveries and FDA approvals of immune checkpoint inhibitors, chimeric antigen receptor T-cells, and oncolytic virotherapy have significantly attracted attention and research directions toward the immunotherapeutic approach to TNBC. Here in this review different aspects of TNBC immunotherapies including the host immune system-tumor interactions, the tumor microenvironment, the relevant molecular targets for immunotherapy, and clinical trials in the field are discussed.

show abstract

Lambda bacteriophage nanoparticles displaying GP2, a HER2/neu derived peptide, induce prophylactic and therapeutic activities against TUBO tumor model in mice

Cited by 24 publications

References 57 publications

The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies

The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies

Keeping It Together: Structures, Functions, and Applications of Viral Decoration Proteins

Single peptides and combination modalities for triple negative breast cancer

Contact Info

Product

Resources

About